INDV Indivior Pharmaceuticals, Inc.

Overview and Growth

In fiscal 2025, Indivior Pharmaceuticals, Inc. recorded $1.24B of revenue, net income of $210.00M, and an operating cash outflow of $27.00M. The $1.24B revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. Compared with $1.19B in fiscal 2024, revenue recorded a 4.3% year-over-year increase. The company reported diluted EPS of $1.64, adding a shareholder-level measure to the absolute income figures considered below. At period end, total assets were $1.20B, framing the scale of the company’s operating and financing commitments. The revenue-to-assets relationship was 1.03x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

After reported cost of revenue, the company retained $994.00M as gross profit before recognizing operating expenses and other items. Gross margin was 80.2%, so that share of each revenue unit remained after the cost of revenue reported for the period. The reported operating result was $262.00M, capturing profitability after direct costs and the operating expenses reflected in the statements. Operating margin measured 21.1%, showing the portion of revenue preserved after the full set of operating costs. The bottom-line result was net income of $210.00M, after the operating, financing, tax, and other items recognized for the period. Net margin was 16.9%, meaning that this portion of revenue remained as net income after all recognized expenses. Before income taxes, the company reported $239.00M of earnings, providing a bridge between the operating result and final net income. Pretax income represented 19.3% of revenue, placing earnings before tax in the context of the company’s operating scale. The reported income-tax provision was $29.00M, the amount recognized between pretax income and the final net-income result. The income-tax provision equaled 12.1% of pretax income, showing the tax burden absorbed by the year’s earnings. The net-income-to-assets relationship measured 17.5%, showing earnings relative to the full balance sheet.

Liquidity and Capital Structure

At period end, the $1.20B asset base was financed through $1.30B of liabilities and -$98.00M of equity. With total equity at -$98.00M, the company carried a negative book-capital position, increasing its reliance on liabilities and future earnings. The near-term balance sheet paired $652.00M of current assets with $914.00M of current liabilities at the reporting date. The current ratio was 0.71x; current liabilities exceeded current assets, leaving a short-term liquidity deficit. The company held $195.00M in cash and equivalents, a narrower liquidity measure than total current assets. The cash balance equaled 21.3% of current liabilities, showing how much near-term coverage came from cash alone. Borrowings totaled $319.00M, adding a fixed financing obligation alongside the company’s equity capital. Relative to total assets, debt measured 26.6%, showing how much of the asset base was matched by borrowing. The liabilities-to-assets relationship was 108.2%, placing reported obligations against the full positive asset balance. Measured against total assets, cash and equivalents represented 16.2%, a balance-sheet composition measure rather than a liquidity forecast. Compared with $1.32B in fiscal 2024, the current asset base moved 8.7% and finished lower. Cash and equivalents were 38.9% lower than fiscal 2024 cash of $319.00M, showing the year-over-year change in liquid resources.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $27.00M, rather than cash generation from operations. Capital spending of $66.00M added to the period’s operating cash use, reinforcing the overall cash deficit after investment for the year. Operating cash flow and capital spending combined to leave a $93.00M cash deficit after capital spending. Relative to revenue, the post-investment cash deficit represented 7.5%. The free-cash-flow deficit equaled 7.7% of total assets, placing the cash shortfall against the company’s resource base.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Sep 24, 2026.